News
SIBN
25.18
-1.64%
-0.42
Weekly Report: what happened at SIBN last week (1102-1106)?
Weekly Report · 1d ago
Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%
NASDAQ · 6d ago
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Neurocrine (NBIX) and SI-Bone (SIBN)
TipRanks · 11/03 18:10
SI-BONE Is Maintained at Buy by UBS
Dow Jones · 11/03 16:21
UBS Maintains Buy on SI-BONE, Raises Price Target to $26
Benzinga · 11/03 16:11
SI-BONE Is Maintained at Buy by TD Cowen
Dow Jones · 11/03 16:10
TD Cowen Maintains Buy on SI-BONE, Raises Price Target to $23
Benzinga · 11/03 15:59
SI-Bone price target raised to $23 from $20 at TD Cowen
TipRanks · 11/03 13:45
SI-Bone (SIBN) Gets a Buy from TD Cowen
TipRanks · 11/03 13:38
SI-Bone price target raised to $26 from $25 at UBS
TipRanks · 11/03 12:40
SI-BONE Price Target Cut to $26.00/Share From $27.00 by Needham
Dow Jones · 11/03 12:24
SI-BONE Is Maintained at Buy by Needham
Dow Jones · 11/03 12:24
Needham Maintains Buy on SI-BONE, Lowers Price Target to $26
Benzinga · 11/03 12:14
SI-Bone Q3 Loss Narrows As Revenue Rises 14.5%; Reaffirms FY26 Revenue Outlook
NASDAQ · 11/03 06:59
SiBone Q3 Earnings Call Highlights
NASDAQ · 11/03 01:14
SI-BONE Q3 2026 Earnings Call Transcript
Benzinga · 11/02 23:00
*SI-BONE 3Q Loss/Shr 8c >SIBN
Dow Jones · 11/02 21:09
*SI-BONE 3Q Loss $3.62M >SIBN
Dow Jones · 11/02 21:09
Press Release: SI-BONE, Inc. Reports Financial -2-
Dow Jones · 11/02 21:09
Press Release: SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance
Dow Jones · 11/02 21:09
More
Webull provides a variety of real-time SIBN stock news. You can receive the latest news about Si-Bone through multiple platforms. This information may help you make smarter investment decisions.
About SIBN
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.